Experts Speculate On Cause Of Neurological Damage in FAAH Inhibitor Study
This article was originally published in Scrip
Executive Summary
The French expert committee set up to look at the preclinical data on Bial's FAAH inhibitor, BIA 10-2474, says that the adverse events that led to the death of one volunteer and the hospitalization of several others in a Phase I study of the drug could be attributable either to an action of the compound beyond FAAH inhibition or to the effects exerted by a metabolite.